Multiple endocrine neoplasia type 2: A review.
Mathiesen JS, Effraimidis G, Rossing M, Rasmussen ÅK, Hoejberg L, Bastholt L, Godballe C, Oturai P, Feldt-Rasmussen U.
Semin Cancer Biol. 2022 Feb;79:163-179. doi: 10.1016/j.semcancer.2021.03.035. Epub 2021 Apr 1.
Update on multiple endocrine neoplasia Type 1 and 2.
Al-Salameh A, Baudry C, Cohen R.
Presse Med. 2018 Sep;47(9):722-731. doi: 10.1016/j.lpm.2018.03.005. Epub 2018 Jun 13.
Non-mammalian models of multiple endocrine neoplasia type 2.
Das TK, Cagan RL.
Endocr Relat Cancer. 2018 Feb;25(2):T91-T104. doi: 10.1530/ERC-17-0411.
Multiple endocrine neoplasia type 2: an overview.
Moline J, Eng C.
Genet Med. 2011 Sep;13(9):755-64. doi: 10.1097/GIM.0b013e318216cc6d.
Genetics of Multiple Endocrine Neoplasia Type 1/Multiple Endocrine Neoplasia Type 2 Syndromes.
Hyde SM, Cote GJ, Grubbs EG.
Endocrinol Metab Clin North Am. 2017 Jun;46(2):491-502. doi: 10.1016/j.ecl.2017.01.011. Epub 2017 Mar 18.
Multiple endocrine neoplasia type 2: towards a risk-based approach integrating molecular and biomarker results.
Machens A, Dralle H.
Curr Opin Oncol. 2024 Jan 1;36(1):1-12. doi: 10.1097/CCO.0000000000001009. Epub 2023 Nov 3.
Multiple endocrine neoplasia type 2.
Wohllk N, Schweizer H, Erlic Z, Schmid KW, Walz MK, Raue F, Neumann HP.
Best Pract Res Clin Endocrinol Metab. 2010 Jun;24(3):371-87. doi: 10.1016/j.beem.2010.02.001.
Multiple endocrine neoplasia type 2.
Gertner ME, Kebebew E.
Curr Treat Options Oncol. 2004 Aug;5(4):315-25. doi: 10.1007/s11864-004-0022-6.
Pheochromocytomas in Multiple Endocrine Neoplasia Type 2.
Tsang VH, Tacon LJ, Learoyd DL, Robinson BG.
Recent Results Cancer Res. 2015;204:157-78. doi: 10.1007/978-3-319-22542-5_7.
Multiple endocrine neoplasia type 2.
Peczkowska M, Januszewicz A.
Fam Cancer. 2005;4(1):25-36. doi: 10.1007/s10689-005-0656-y.
